yl23455永利官网

    洞察市场格局
    解锁药品研发情报

    免费客服电话

    18983288589
    医药数据查询

    【ChiCTR2500096375】Diagnostic Efficacy and Cost-effectiveness of Artificial Intelligence Systems in Diabetic Retinopathy Screening in Low-Resource Settings: A Multicenter Randomized Controlled Trail

    基本信息
    登记号

    ChiCTR2500096375

    试验状态

    正在进行

    药物名称

    /

    药物类型

    /

    规范名称

    /

    首次公示信息日的期

    2025-01-22

    临床申请受理号

    /

    靶点

    /

    适应症

    Diabetic retinal disease

    试验通俗题目

    Diagnostic Efficacy and Cost-effectiveness of Artificial Intelligence Systems in Diabetic Retinopathy Screening in Low-Resource Settings: A Multicenter Randomized Controlled Trail

    试验专业题目

    Diagnostic Efficacy and Cost-effectiveness of Artificial Intelligence Systems in Diabetic Retinopathy Screening in Low-Resource Settings: A Multicenter Randomized Controlled Trail

    申办单位信息
    申请人联系人
    申请人名称
    联系人邮箱
    联系人邮编

    联系人通讯地址
    临床试验信息
    试验目的

    To evaluate the effectiveness, cost-efficiency, and performance of an AI system in detecting VTDR and DME through FP and OCT in a screening unit.

    试验分类
    试验类型

    随机平行对照

    试验分期

    诊断试验新技术

    随机化

    A statistician independent of the study team will generate a computer-based random allocation sequence, stratified by age and visual acuity to ensure balanced allocation across the groups.

    盲法

    The research assistant will send the participant's stratification information, including age group and VA category, to the study coordinator. The study coordinator will then assign the participant to one of the three groups according to the randomization schedule and notify the research assistant of the group assignment. The study coordinator will manage the flow of information to ensure appropriate allocation of imaging resources. For participants in Intervention Groups 1 and 2, AI-generated reports from both the AI-FP and AI-OCT systems will be provided to the clinicians before making triage decisions. In the Control Group, clinicians will make decisions based solely on their interpretation of the FPs without AI assistance.

    试验项目经费来源

    Departmental fund

    试验范围

    /

    目标入组人数

    354

    实际入组人数

    /

    第一例入组时间

    2024-10-01

    试验终止时间

    2025-02-28

    是否属于一致性

    /

    入选标准

    1) Individuals diagnosed with diabetes mellitus 2) Age 18 years or older；

    排除标准

    1) Individuals with other ocular diseases that are sight-threatening and require urgent treatment, such as wet age-related macular degeneration, retinal detachment, vitreo-macular traction, foveoschisis, retinal vein occlusion, retinal artery occlusion 2) Individuals who refuse or are unable to provide informed consent；

    研究者信息
    研究负责人姓名
    试验机构

    Binh Dinh Eye Hospital

    研究负责人电话
    研究负责人邮箱
    研究负责人邮编

    /

    联系人通讯地址

    最新临床资讯

    yl23455永利官网企业版
    50亿+条医药数据随时查
    7天免费试用
    体验产品